Form 4 Tracker
RA Capital Nexus Fund III, L.P.

Director; Director, 10% Owner · 18 filings · Latest: Jun 29, 2026

Artiva Biotherapeutics, Inc.
Bicara Therapeutics Inc.
Climb Bio, Inc.
Evommune, Inc.
Mineralys Therapeutics, Inc.
Parabilis Medicines, Inc.
Septerna, Inc.
Sionna Therapeutics, Inc.
SpyGlass Pharma, Inc.
TickerOwnerRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Filing
SION
RA Capital Nexus Fund III, L.P.Oct 24, 2025
Proposed Sale
$39.2166,672$2.6M

← Previous

Page 2 of 2